Lin Liu

Prof. Lin Liu


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
LLLiu Liu
Liu Liu
WLWei Lu
Wei Lu
SMShengyuan Miao
Shengyuan Miao
YYYang Yu
Yang Yu
XZXu-Bing Zhang
Xu-Bing Zhang
LLLin Liu
Lin Liu
RNA-binding proteins play critical roles in RNA processing and are aberrantly expressed in colorectal cancer (CRC). Through comprehensive analysis of multiple gene expression datasets (GSE20916, GSE18105, GSE21510, TCGA-COAD and TCGA-READ), NCBP2 was identified as a potential tumorigenic gene in CRC. NCBP2 expression was significantly elevated in CRC tissues, correlated with tumour invasion and metastasis, and associated with poor patient survival outcomes. Furthermore, overexpression of NCBP2 in CRC cells was shown to increase cell proliferation, migration, and tumour invasion in both in vitro and in vivo models. Mechanistically, the NCBP2 protein stabilised LIPG mRNA via direct binding to the m7G motif in the 5’-cap structure of LIPG mRNA, thereby increasing LIPG expression. Additionally, NCBP2 promoted lipid droplet accumulation in CRC cells in a LIPG-dependent manner. These findings collectively suggest that the NCBP2-LIPG-lipid droplet axis represents a novel mechanism underlying CRC progression and metastasis, providing a promising therapeutic target for CRC treatment.

19 February 2026 in Clinics
Verified
Journal Article
Open access
LLLiu Liu
Liu Liu
SFShijie Feng
Shijie Feng
HWHaiyan Wang
Haiyan Wang
LLLin Liu
Lin Liu
Whether Totally Laparoscopic Gastrectomy (TLG) is beneficial for patients with gastric cancer remains not fully understood. This study was to evaluate the advantages of Totally Laparoscopic Gastrectomy (TLG) for treating Gastric Cancer (GC). From January 2019 to December 2021, 380 patients with gastric cancer were included into this study (190 per group). The outcomes of interest, including postoperative recovery, inflammation, and oncological results, were compared between the two groups. The patient baselines between the two groups were comparable. The TLG group had lower risks of wound infection (p = 0.02) and total complications (p = 0.03) compared to LAG. The TLG group exhibited significantly shorter operative time (median: 215 vs. 240 min, p < 0.001), less intraoperative blood loss (median: 50 vs. 100 mL, p < 0.001), shorter time to first flatus (median: 3 vs. 4 days, p < 0.001), and reduced length of postoperative hospital stay (p < 0.001). Furthermore, patients in the TLG group exhibited lower White Blood Cell (WBC) counts on POD 1 compared to patients in the LAG group (mean 11.74 vs. 12.75 × 10^9/L; p = 0.003). Multivariate logistic regression analysis revealed that TLG was an independent predictor of shorter postoperative hospitalization (OR (95% CI): 0.54 (0.30‒0.95), p = 0.03). Interestingly, the TLG group had more lymph nodes harvested than the LAG group (median (range): 23 (2‒88) vs. 23 (2‒88), p < 0.001). This study demonstrates that TLG has a lower risk of complications and faster postoperative recovery, thus TLG is superior to LAG for the treatment of gastric cancer.